



GlaxoSmithKline Pharmaceuticals Limited  
GSK House, Dr. Annie Besant Road,  
Worli, Mumbai - 400 030  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: [www.gsk-india.com](http://www.gsk-india.com)  
Email: [askus@gsk.com](mailto:askus@gsk.com)

9<sup>th</sup> July 2025

To,

**BSE LIMITED**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sir,

Subject: **Change in Senior Managerial Personnel - Regulation 30 of LODR**

In compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby inform you that Mr. Vishwanath Swarup has been appointed as Commercial Head - General Medicines effective today.

**Brief Profile:**

Vishwanath has a wealth of experience in business strategy, Operations and commercial leadership. Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines. Prior to that he held leadership roles at Abbott as Commercial Director - India Pharmaceuticals, and at Max Bupa as Vice President – Strategy, Transformation Product. His career also includes impactful stints with McKinsey & Company (Consultant), Pfizer Consumer (Commercial Operations), and Unilever (Supply Chain Development Manager). Vishwanath has worked across global locations including Chicago, Jefferson City, NCR, and Mumbai.

He has done MBA from Kellogg School of Management, Northwestern University, MS in Industrial & Systems Engineering from Ohio State University & BS in Mechanical Engineering from RV College of Engineering.

The additional details required under the SEBI Listing Regulations read with SEBI Circular Nos. CIR/CFD/CMD/412015 dated September 9, 2015 and Exchange Circular List/Comp/14/2018-19 dated June 20, 2018, are enclosed herewith.

Particulars	Mr. Vishwanath Swarup
Reason for change	Appointment
Date of appointment	9 <sup>th</sup> July 2025
Brief Profile	As above
Disclosure of relationship between Directors	NIL

Kindly take the above intimation on your records.

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President – Administration, Real Estate  
& Company Secretary

CIN: L24239MH1924PLC001151